Arbutus Biopharma Corp Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Arbutus Biopharma Corp (ABUS) holds an ST Score of 69.5 out of 100 (B+), with its strongest factor being Profitability (A+) and its weakest Valuation (D+). Analysts rate ABUS Buy across 10 ratings with a $8.50 average price target (+0.7% vs the current $5.00).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD+
All factor grades
- ProfitabilityA+
- Financial StrengthA
- MomentumA
- ForecastB+
- GrowthB
- ValuationD+
- Piotroski5/9
Contact
ABUS stock: frequently asked questions
What is ABUS's ST Score?
Arbutus Biopharma Corp (ABUS) has an ST Score of 69.5 out of 100, an overall grade of B+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ABUS a buy, sell, or hold?
Wall Street's consensus rating on ABUS is Buy based on 10 analyst ratings. Our own ST Score grades it B+ (69.5/100). This is data, not investment advice — always do your own research.
What is ABUS's valuation grade?
Arbutus Biopharma Corp (ABUS) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ABUS's growth grade?
Arbutus Biopharma Corp (ABUS) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ABUS's profitability grade?
Arbutus Biopharma Corp (ABUS) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ABUS's financial strength grade?
Arbutus Biopharma Corp (ABUS) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ABUS?
The average analyst price target for Arbutus Biopharma Corp (ABUS) is $8.50 from 10 analysts, which is +0.7% versus the recent price of $5.00.
What is ABUS's Piotroski score?
Arbutus Biopharma Corp (ABUS) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.